Marshall Wace LLP cut its holdings in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF – Free Report) by 31.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 298,829 shares of the company’s stock after selling 135,753 shares during the quarter. Marshall Wace LLP owned approximately 0.67% of Cardiff Oncology worth $663,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRDF. Callan Capital LLC lifted its stake in shares of Cardiff Oncology by 37.2% during the 1st quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock valued at $228,000 after buying an additional 11,600 shares in the last quarter. Blair William & Co. IL raised its holdings in Cardiff Oncology by 32.4% during the 1st quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock valued at $919,000 after acquiring an additional 42,180 shares during the period. Vanguard Group Inc. lifted its position in shares of Cardiff Oncology by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock worth $10,260,000 after acquiring an additional 9,468 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Cardiff Oncology by 380.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after acquiring an additional 962,940 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Cardiff Oncology in the second quarter valued at $256,000. Institutional investors own 16.29% of the company’s stock.
Cardiff Oncology Price Performance
NASDAQ CRDF opened at $2.74 on Wednesday. The company’s 50 day simple moving average is $2.40 and its two-hundred day simple moving average is $3.14. Cardiff Oncology, Inc. has a 1 year low of $0.94 and a 1 year high of $6.42. The stock has a market capitalization of $127.55 million, a PE ratio of -2.92 and a beta of 1.96.
Analysts Set New Price Targets
Separately, Craig Hallum assumed coverage on Cardiff Oncology in a report on Friday, September 6th. They set a “buy” rating and a $8.00 price objective on the stock.
Read Our Latest Report on Cardiff Oncology
About Cardiff Oncology
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
See Also
- Five stocks we like better than Cardiff Oncology
- What is Insider Trading? What You Can Learn from Insider Trading
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What Are Dividend Achievers? An Introduction
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- 3 REITs to Buy and Hold for the Long Term
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.